



Mark JC Nuijten, PhD, MD, MBA, is founder of **Ars Accessus Medica** and **Minerva International Health Economic Network**. Dr. Nuijten has formal collaboration with **Erasmus University** in Rotterdam. **Dr. Nuijten** was trained as a physician and worked in clinical research before obtaining his international M.B.A. from **Erasmus University, Rotterdam**. He obtained his PhD in health economics (2003) on the thesis “In search for more confidence in health economic modelling” at the **Erasmus University, Rotterdam**. Recently Dr. Nuijten was Board Director of **ISPOR** (2002-2004) and Chair of the Management Board of **Value in Health** (2002-2004). Currently he is member of the Editorial Advisory Board of **Value in Health** and **ISPOR Connections**. He is member of Leadership Group of the **Global Health Care Reimbursement Systems and Decision Processes ISPOR Working Group**.

Dr. Nuijten provides international consulting services in Health Economics, Outcomes Research, Pricing & Reimbursement and Strategic Product Planning. He is pursuing the development of economic modelling and broadening their application in health care. An example is the development of a Pricing Matrix Model for pricing research in early phase development. He established global collaborations with key opinion leaders in the key European markets, as well as the US, Canada and Japan.

Prior to setting up **Ars Accessus Medica**, Dr. Nuijten was a partner with **MEDTAP International**. As a Director of Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for **MEDTAP**. Before his **MEDTAP** period, Dr. Nuijten was a Managing Director of the **Quintiles** office in

the Netherlands, which included the health economic divisions **Benefit Research Group** and **The Lewin Group**. Dr. Nuijten had global responsibility for health economic modeling in which he established a center of excellence for the company.

Dr. Nuijten has developed and organized several training programs in health economics and disease management for the **Drug Information Association** (DIA) and for individual pharmaceutical companies. He is the author of numerous articles in *Pharmacoeconomics* and leading medical journals. In 1998, Dr. Nuijten contributed to the development of the Dutch pharmacoeconomic guidelines to be used in the reimbursement decision-making process. In 1999, he has acted as an adviser to Erasmus University, Rotterdam, for the development of a Dutch health economic costing manual. Dr. Nuijten is also a co-founder of **Prosper**, a Dutch task force promoting the use of health economics in healthcare decision making.